These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 26781346

  • 1. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J.
    Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855
    [Abstract] [Full Text] [Related]

  • 4. Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.
    Al-Salama ZT, Keam SJ.
    Clin Drug Investig; 2019 Oct 26; 39(10):1009-1018. PubMed ID: 31489570
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 26; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 8. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y.
    Ai Zheng; 2006 Apr 26; 25(4):495-500. PubMed ID: 16613688
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z, Grecea D, Smakal M, Tjulandin S, Bondarenko I, Perjesi L, Illes A, Horvat-Karajz K, Aradi I.
    BMC Cancer; 2019 Feb 06; 19(1):122. PubMed ID: 30727980
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis.
    Gu X, Zhang Y.
    Ann Palliat Med; 2021 Jul 06; 10(7):7841-7846. PubMed ID: 34353071
    [Abstract] [Full Text] [Related]

  • 11. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L.
    Cancer Chemother Pharmacol; 2018 Oct 06; 82(4):607-613. PubMed ID: 30043207
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y.
    Thorac Cancer; 2022 Jan 06; 13(1):117-125. PubMed ID: 34791805
    [Abstract] [Full Text] [Related]

  • 13. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group.
    Ann Oncol; 2003 Jan 06; 14(1):29-35. PubMed ID: 12488289
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer.
    Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL.
    Int J Clin Pharmacol Ther; 2024 Mar 06; 62(3):115-121. PubMed ID: 38263810
    [Abstract] [Full Text] [Related]

  • 15. A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients.
    Wang T, Wu B, Hu X, Liu J, Zhang T, Li F, Sun B, Cai L, Li X, Chen Z, Yang Q, Jiang Z.
    Ann Transl Med; 2019 May 06; 7(9):196. PubMed ID: 31205914
    [Abstract] [Full Text] [Related]

  • 16. Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.
    Yang S, Chen SS, Zhang CG, Zhou YL, Xiu M, Zhang P.
    Br J Clin Pharmacol; 2024 Oct 06; 90(10):2621-2629. PubMed ID: 38925586
    [Abstract] [Full Text] [Related]

  • 17. Pegylated recombinant human granulocyte colony-stimulating factor for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy: a prospective study.
    You J, Yuan Y, Gu X, Wang W, Li X.
    BMC Cancer; 2024 Jul 12; 24(1):833. PubMed ID: 38997665
    [Abstract] [Full Text] [Related]

  • 18. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 19. Prophylactic administration of mecapegfilgrastim after chemotherapy in patients with lymphoma.
    Zheng M, Wen X, Su L.
    Ann Palliat Med; 2021 Dec 01; 10(12):12055-12060. PubMed ID: 35016412
    [Abstract] [Full Text] [Related]

  • 20. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
    Huang HQ, Bai B, Gao YH, Zou DH, Zou SH, Tan H, Song YP, Li ZY, Jin J, Li W, Su H, Gong YP, Zhong MZ, Shuang YR, Zhu J, Zhang JQ, Cai Z, Teng QL, Sun WJ, Yang Y, Xia ZJ, Chen HL, Hua LM, Bao YY, Wu N.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):825-830. PubMed ID: 29166732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.